The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The BURAN study is a randomized, open-label phase III study to assess the treatment effect of
once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel
alone in patients with refractory, recurrent, or metastatic head and neck squamous cell
carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1 monotherapy; prior
anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential
treatment of anti PD 1/anti PD L1 therapy, either prior to or post, platinum-based therapy.